Loading
Latest filing published 27 Jul 2026 for Scribe Therapeutics, Inc., €18k.
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of David Parrot in Scribe Therapeutics, Inc. In total, 2 filings cover trades dated 23 July 2026.
No open-market sale appears; the market trades are 2 purchases worth €35k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
The record was last updated on 27 July 2026 with an open-market purchase (€18k) in Scribe Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration